RIPK3 and diabetic cardiomyopathy: To examine if targeting RIPK3 is a therapeutic approach to reduce diabetic cardiomyopathy, we gave GSK’872, a pharmacological inhibitor of RIPK3, to STZ-injected mice right after induction of hyperglycemia for a total of 2 months.